Chunxia Su
Tongji University · 252 works · 7,184 citations · h-index 46
Top works
- Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer
- Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer
- Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: A meta‐analysis from six phase III randomized controlled trials
- Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
- ROS1 fusions in Chinese patients with non-small-cell lung cancer
- EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases
- MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
- Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
- Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer
- Continuous inertial cavitation evokes massive ROS for reinforcing sonodynamic therapy and immunogenic cell death against breast carcinoma
- Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients
- Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
- Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes
- KIF5B‐RET fusions in Chinese patients with non–small cell lung cancer
- Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer
- EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies
- Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors
- Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
- Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never‐smoker women with pulmonary adenocarcinoma
- Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes